Shares of Tandem Diabetes Care (NASDAQ: TNDM) surged 9.79% in pre-market trading on Thursday following the release of the company's impressive first-quarter 2025 financial results. The medical device company, which specializes in insulin delivery systems, reported revenue that significantly exceeded Wall Street expectations and demonstrated strong growth across its markets.

Tandem Diabetes Care announced Q1 revenue of $234.42 million, representing a 22.3% year-over-year increase and handily beating the analyst consensus estimate of $220.20 million. The company's performance was driven by robust sales growth both in the United States and international markets. U.S. pump sales grew 22% year-over-year, while sales outside the United States saw an impressive 35% increase.

John Sheridan, President and CEO of Tandem Diabetes Care, commented on the results, stating, "The strength of our first quarter performance was driven by more than 20% worldwide sales growth, including our highest quarter ever outside the United States. We are creating new possibilities for people living with diabetes, while delivering record results that align with our 2025 and long-term financial goals for sustained, double-digit sales growth and profitability." The company also reaffirmed its full-year 2025 revenue guidance of $997 million to $1.007 billion, aligning closely with analysts' expectations and further bolstering investor confidence in the company's growth trajectory.